TRIAL DETAIL
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor |
|||
Status: |
Not yet recruiting |
|||
Phase: |
1/2 |
Start Date 11/01/2024 |
Age of Trial (yrs) 0 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor |
|||
Strategy: |
Block KIT |
|||
Trial Type: |
Specifically GIST and only GIST |
|||
Other Protocol IDs: |
DCC-3009-01-001 |
|||
Sponsor: |
Deciphera |
|||
Patient Contact: |
Name: Clinical Team
785-830-2100
clinicaltrials@deciphera.com |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
||||
IV or Oral: |
Oral |
|||
Trial Notes: |
||||
Trial Links |
Trial Results |
Drug Information |
| AACR Orlando April 2023 Pan-exon mutant KIT inhibitor DCC-3009 demonstrates tumor regressions in preclinical gastrointestinal stromal tumor models |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |